The IHC results demonstrated significant increases of protein expressions of FGF19, FGFR4 and EpCAM in specimens with fatty liver, NASH, cirrhosis, and HCC compared to healthy liver tissue. The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatohepatitis.